Drug Trial Radar · NCT07748208
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jun 15, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.
Conditions
- Breast Cancer
- Diabetes Type II
Interventions
InavolisibDrug
Participants will receive oral inavolisib on Days 2-28 of each 28-day cycle.
FulvestrantDrug
Participants will receive intramuscular (IM) fulvestrant on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28-day cycle.
PalbociclibDrug
Some participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Grade 4 Hyperglycemia Adverse Events (AEs) After Cycle 1Time frame: Up to approximately 21 months
- Percentage of Participants Hospitalized for Hyperglycemia or its Complications After Cycle 1Time frame: Up to approximately 21 months
- Percentage of Participants with AEs After Cycle 1Time frame: Up to approximately 21 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Community Cancer Institute (CCI)
Clovis, California · Recruiting
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, California · Recruiting
MedStar Washington Hosp Center
Washington D.C., District of Columbia · Recruiting
Grady Memorial Hospital
Atlanta, Georgia · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Nebraska Cancer Specialists St Francis - Grand Island
Grand Island, Nebraska · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
NYU Langone Hospital Long Island Clinical Research
Mineola, New York · Recruiting
NYU Langone?s Perlmutter Cancer Center - 160 E 34th St
New York, New York · Recruiting
West Cancer Center & Research Institute
Germantown, Tennessee · Recruiting
West Virginia University
Morgantown, West Virginia · Recruiting
Pan American Center for Oncology Trials, LLC
Dorado, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.